Des anomalies cutanées peuvent survenir en raison de troubles liés à la méthylation.
Anomalies cutanéesMéthylation de l'ADN
Prévention
5
#1
Comment prévenir les anomalies de méthylation ?
Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques.
AlimentationMode de vie
#2
Le stress influence-t-il la méthylation ?
Oui, le stress chronique peut affecter les niveaux de méthylation de l'ADN.
StressMéthylation de l'ADN
#3
Les suppléments nutritionnels aident-ils ?
Certains suppléments, comme l'acide folique, peuvent soutenir une méthylation saine.
Suppléments nutritionnelsAcide folique
#4
L'exercice physique a-t-il un impact ?
Oui, l'exercice régulier peut influencer positivement la méthylation de l'ADN.
Exercice physiqueMéthylation de l'ADN
#5
Les habitudes de sommeil affectent-elles la méthylation ?
Un sommeil de qualité est crucial pour maintenir une méthylation adéquate.
SommeilMéthylation de l'ADN
Traitements
5
#1
Quels traitements ciblent la méthylation ?
Des agents déméthylants comme l'azacitidine sont utilisés pour traiter certains cancers.
Agents déméthylantsCancer
#2
La thérapie génique peut-elle corriger la méthylation ?
Oui, la thérapie génique vise à restaurer la méthylation normale dans certaines conditions.
Thérapie géniqueMéthylation de l'ADN
#3
Y a-t-il des traitements préventifs ?
Des interventions diététiques et des modifications du mode de vie peuvent aider à prévenir des anomalies.
PréventionMode de vie
#4
Les médicaments peuvent-ils influencer la méthylation ?
Oui, certains médicaments peuvent modifier les niveaux de méthylation de l'ADN.
MédicamentsMéthylation de l'ADN
#5
Comment la recherche avance-t-elle sur ce sujet ?
Des études cliniques explorent de nouvelles thérapies ciblant la méthylation pour diverses maladies.
Recherche cliniqueThérapies ciblées
Complications
5
#1
Quelles complications sont liées à la méthylation anormale ?
Des complications incluent le développement de cancers et de maladies auto-immunes.
CancersMaladies auto-immunes
#2
La 5-méthylcytosine est-elle liée à des troubles mentaux ?
Oui, des anomalies de méthylation peuvent contribuer à des troubles mentaux comme la dépression.
Troubles mentauxDépression
#3
Y a-t-il des risques de maladies cardiovasculaires ?
Des études suggèrent un lien entre la méthylation et les maladies cardiovasculaires.
Maladies cardiovasculairesMéthylation de l'ADN
#4
Les complications peuvent-elles être réversibles ?
Certaines complications peuvent être atténuées par des traitements ciblés et des changements de mode de vie.
Traitements ciblésMode de vie
#5
La 5-méthylcytosine affecte-t-elle la fertilité ?
Des modifications de méthylation peuvent influencer la fertilité et le développement embryonnaire.
FertilitéDéveloppement embryonnaire
Facteurs de risque
5
#1
Quels facteurs augmentent le risque de méthylation anormale ?
Des facteurs comme l'âge, l'alimentation et l'exposition à des toxines peuvent augmenter le risque.
ÂgeToxines
#2
Le tabagisme influence-t-il la méthylation ?
Oui, le tabagisme est associé à des modifications de la méthylation de l'ADN.
TabagismeMéthylation de l'ADN
#3
L'environnement joue-t-il un rôle ?
Oui, des facteurs environnementaux comme la pollution peuvent affecter la méthylation.
EnvironnementPollution
#4
Les antécédents familiaux influencent-ils le risque ?
Oui, des antécédents familiaux de maladies peuvent augmenter le risque de méthylation anormale.
Antécédents familiauxMaladies
#5
Le mode de vie a-t-il un impact sur la méthylation ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter la méthylation.
Mode de vieAlimentation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "5-Méthyl-cytosine : Questions médicales les plus fréquentes",
"headline": "5-Méthyl-cytosine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 5-Méthyl-cytosine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-31",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "5-Méthyl-cytosine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cytosine",
"url": "https://questionsmedicales.fr/mesh/D003596",
"about": {
"@type": "MedicalCondition",
"name": "Cytosine",
"code": {
"@type": "MedicalCode",
"code": "D003596",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.742.698.421"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "5-Méthyl-cytosine",
"alternateName": "5-Methylcytosine",
"code": {
"@type": "MedicalCode",
"code": "D044503",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yun-Gui Yang",
"url": "https://questionsmedicales.fr/author/Yun-Gui%20Yang",
"affiliation": {
"@type": "Organization",
"name": "CAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, College of Future Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China; Sino-Danish College, University of Chinese Academy of Sciences, Beijing 101408, China; Institute of Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: ygyang@big.ac.cn."
}
},
{
"@type": "Person",
"name": "Ying Yang",
"url": "https://questionsmedicales.fr/author/Ying%20Yang",
"affiliation": {
"@type": "Organization",
"name": "CAS Key Laboratory of Genomic and Precision Medicine, College of Futuer Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China."
}
},
{
"@type": "Person",
"name": "Qing Dai",
"url": "https://questionsmedicales.fr/author/Qing%20Dai",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Chicago, Chicago, IL 60637."
}
},
{
"@type": "Person",
"name": "Chuan He",
"url": "https://questionsmedicales.fr/author/Chuan%20He",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Chicago, Chicago, IL 60637."
}
},
{
"@type": "Person",
"name": "Bao-Fa Sun",
"url": "https://questionsmedicales.fr/author/Bao-Fa%20Sun",
"affiliation": {
"@type": "Organization",
"name": "CAS Key Laboratory of Genomic and Precision Medicine, College of Futuer Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid for percutaneous nephrolithotomy.",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/37882229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015122.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid: Beyond antifibrinolysis.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35834488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/trf.16976"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prehospital Tranexamic Acid for Severe Trauma.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2215457"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid in pediatric hemorrhagic trauma.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36044459",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/TA.0000000000003775"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma.",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/35340120",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.14942"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pyrimidines",
"item": "https://questionsmedicales.fr/mesh/D011743"
},
{
"@type": "ListItem",
"position": 5,
"name": "Pyrimidinones",
"item": "https://questionsmedicales.fr/mesh/D011744"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytosine",
"item": "https://questionsmedicales.fr/mesh/D003596"
},
{
"@type": "ListItem",
"position": 7,
"name": "5-Méthyl-cytosine",
"item": "https://questionsmedicales.fr/mesh/D044503"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 5-Méthyl-cytosine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 5-Méthyl-cytosine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 5-Méthyl-cytosine",
"description": "Comment détecte-t-on la 5-méthylcytosine ?\nQuels tests sont utilisés pour évaluer la méthylation ?\nLa 5-méthylcytosine est-elle mesurable dans le sang ?\nQuels biomarqueurs sont associés à la 5-méthylcytosine ?\nLa 5-méthylcytosine est-elle liée à des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 5-Méthyl-cytosine",
"description": "Quels symptômes sont liés à la méthylation anormale ?\nLa 5-méthylcytosine affecte-t-elle le comportement ?\nY a-t-il des signes cliniques de dysfonctionnement ?\nLa 5-méthylcytosine est-elle liée à des symptômes neurologiques ?\nPeut-on observer des symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 5-Méthyl-cytosine",
"description": "Comment prévenir les anomalies de méthylation ?\nLe stress influence-t-il la méthylation ?\nLes suppléments nutritionnels aident-ils ?\nL'exercice physique a-t-il un impact ?\nLes habitudes de sommeil affectent-elles la méthylation ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 5-Méthyl-cytosine",
"description": "Quels traitements ciblent la méthylation ?\nLa thérapie génique peut-elle corriger la méthylation ?\nY a-t-il des traitements préventifs ?\nLes médicaments peuvent-ils influencer la méthylation ?\nComment la recherche avance-t-elle sur ce sujet ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 5-Méthyl-cytosine",
"description": "Quelles complications sont liées à la méthylation anormale ?\nLa 5-méthylcytosine est-elle liée à des troubles mentaux ?\nY a-t-il des risques de maladies cardiovasculaires ?\nLes complications peuvent-elles être réversibles ?\nLa 5-méthylcytosine affecte-t-elle la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 5-Méthyl-cytosine",
"description": "Quels facteurs augmentent le risque de méthylation anormale ?\nLe tabagisme influence-t-il la méthylation ?\nL'environnement joue-t-il un rôle ?\nLes antécédents familiaux influencent-ils le risque ?\nLe mode de vie a-t-il un impact sur la méthylation ?",
"url": "https://questionsmedicales.fr/mesh/D044503?mesh_terms=Tranexamic+Acid#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on la 5-méthylcytosine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La détection se fait par des techniques comme la bisulfite séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la méthylation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme le PCR en temps réel et le séquençage de nouvelle génération sont utilisés."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine est-elle mesurable dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des échantillons sanguins peuvent être analysés pour la méthylation de l'ADN."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont associés à la 5-méthylcytosine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs comme les gènes régulés par la méthylation peuvent être identifiés."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine est-elle liée à des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est associée à des maladies comme le cancer et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à la méthylation anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des troubles cognitifs et des anomalies de développement."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine affecte-t-elle le comportement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des modifications de la méthylation peuvent influencer le comportement et l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques de dysfonctionnement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes peuvent inclure des troubles métaboliques et des problèmes immunitaires."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine est-elle liée à des symptômes neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est impliquée dans des maladies neurodégénératives et des troubles psychiatriques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent survenir en raison de troubles liés à la méthylation."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies de méthylation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il la méthylation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter les niveaux de méthylation de l'ADN."
}
},
{
"@type": "Question",
"name": "Les suppléments nutritionnels aident-ils ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme l'acide folique, peuvent soutenir une méthylation saine."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut influencer positivement la méthylation de l'ADN."
}
},
{
"@type": "Question",
"name": "Les habitudes de sommeil affectent-elles la méthylation ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil de qualité est crucial pour maintenir une méthylation adéquate."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la méthylation ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents déméthylants comme l'azacitidine sont utilisés pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger la méthylation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique vise à restaurer la méthylation normale dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interventions diététiques et des modifications du mode de vie peuvent aider à prévenir des anomalies."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils influencer la méthylation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent modifier les niveaux de méthylation de l'ADN."
}
},
{
"@type": "Question",
"name": "Comment la recherche avance-t-elle sur ce sujet ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études cliniques explorent de nouvelles thérapies ciblant la méthylation pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à la méthylation anormale ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent le développement de cancers et de maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine est-elle liée à des troubles mentaux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de méthylation peuvent contribuer à des troubles mentaux comme la dépression."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre la méthylation et les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être atténuées par des traitements ciblés et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "La 5-méthylcytosine affecte-t-elle la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications de méthylation peuvent influencer la fertilité et le développement embryonnaire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de méthylation anormale ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, l'alimentation et l'exposition à des toxines peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la méthylation ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à des modifications de la méthylation de l'ADN."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la pollution peuvent affecter la méthylation."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque de méthylation anormale."
}
},
{
"@type": "Question",
"name": "Le mode de vie a-t-il un impact sur la méthylation ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter la méthylation."
}
}
]
}
]
}
CAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, College of Future Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China; Sino-Danish College, University of Chinese Academy of Sciences, Beijing 101408, China; Institute of Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: ygyang@big.ac.cn.
CAS Key Laboratory of Genomic and Precision Medicine, College of Futuer Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
CAS Key Laboratory of Genomic and Precision Medicine, College of Futuer Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; CAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, College of Future Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China; Sino-Danish College, University of Chinese Academy of Sciences, Beijing 101408, China.
CAS Key Laboratory of Genomic and Precision Medicine, College of Futuer Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
University of Chinese Academy of Sciences, Beijing, China.
EMBL-Australia Collaborating Group, Department of Genome Sciences, John Curtin School of Medical Research, Australian National University, Canberra, 2601, Australian Captial Territory, Australia. thomas.preiss@anu.edu.au.
Victor Chang Cardiac Research Institute, Sydney, New South Wales, 2010, Australia. thomas.preiss@anu.edu.au.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Chinese Academy of Sciences, Beijing, China.
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China.
University of Chinese Academy of Sciences, Beijing, China.
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China.
CAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, College of Future Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
University of Chinese Academy of Sciences, Beijing, China.
Institute of Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.
State Key Laboratory of Molecular Biology, Shanghai Key Laboratory of Molecular Andrology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China. huangy@sibcb.ac.cn.
Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Tongji Hospital, Clinical Center for Brain and Spinal Cord Research, School of Medicine, Tongji University, Shanghai 200092, China.
Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and sh...
To assess the effects of TXA in individuals with kidney stones undergoing PCNL....
We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and c...
We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old....
Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone-free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adv...
We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract ...
Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, a...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients. TXA binds plasminogen and preve...
Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopath...
We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, ...
A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned ...
Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8...
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with improved outcomes. The evidence for TXA use in injured children is limited t...
Melasma is an acquired pigmentation disorder with a complex multifactorial etiopathogenesis. Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combi...
To provide evidence of the efficacy and safety of oral TA as a monotherapy, and in combination with a triple combination cream, for treating melasma in the Hispanic population....
Forty-four female Hispanic patients with melasma were randomly assigned to receive 325 mg of oral TA every 12 h plus f-TCC (fluocinolone-based triple combination cream) every 24 h (group A) or 325 mg ...
There was a 50.04% and 65.45% improvement in mMASI at Weeks 4 and 8, respectively, in group A, compared to baseline, while for Week 16, an improvement of 76.85% was achieved in group B compared to bas...
The combination of oral TA and f-TCC is more effective than oral TA alone in the treatment of severe melasma in Hispanic patients....
In the last decades, tranexamic acid (TXA) has emerged as an essential tool in blood loss management in obstetrics. TXA prophylaxis for postpartum haemorrhage (PPH) has been studied in double-blind, p...
Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on pa...
Tranexamic acid (TXA) is a common haemorrhage control agent in both emergency department (ED) settings and intra-operatively. While efficacy and potential harms are well-studied, there are no overview...
Tranexamic acid reduces surgical bleeding. Consistent with previous research, the POISE-3 (Peri-Operative Ischemic Evaluation-3) trial found that tranexamic acid reduces major bleeding by 25% and with...
Melasma is a hyperpigmentary disorder causing cosmetic disfigurement. We aimed to compare the efficacy and safety of tranexamic acid (TXA) microinjections with TXA mesoneedling for facial melasma....
This randomized assessor-blind split-face controlled trial included patients with symmetric facial melasma. One side of the face received TXA (100 mg/ml) mesoneedling and the other side intradermal TX...
All 27 patients included in the study were female (mean age: 44.22 ± 8.39 years). Both groups were comparable in terms of mMASI scores before and after treatment (standardized mean difference [SMD] = ...
TXA mesoneedling was comparable with TXA microinjection in the treatment of facial melasma, while patient satisfaction was significantly higher with TXA mesoneedling; however, the high frequency of co...